Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy.
Analysis of CD4 cell responses during 48 weeks of enfuvirtide therapy after virological failure (analysis of covariance) demonstrated significant associations between V38 mutations (n = 58 subjects) and continued CD4 cell increases and between Q40 mutations (n = 8) and loss of CD4 cell benefit (+34 versus -95 cells/mul, P < 0.001). Subjects with N43 (n = 20) or other mutations (n = 48) had intermediate CD4 cell responses. These data suggest that key enfuvirtide resistance mutations may be associated with reduced viral pathogenicity in vivo.
Melby
Thomas E
TE
Trimeris Inc., Morrisville, North Carolina, USA.
Despirito
Michael
M
Demasi
Ralph A
RA
Heilek
Gabrielle
G
Thommes
James A
JA
Greenberg
Michael L
ML
Graham
Neil
N
D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D024882:Drug Resistance, Viral / Q000235:genetics*; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D009154:Mutation; D010446:Peptide Fragments / Q000627:therapeutic use*; D012189:Retrospective Studies
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide